| アイテムタイプ |
紀要論文 / departmental bulletin paper(1) |
| 公開日 |
2025-04-28 |
| タイトル |
|
|
タイトル |
Development and characterization of an antibody specifically recognizing a mutant EGFR (L858R) protein expressed frequently in non-small cell lung cancer |
|
言語 |
en |
| 作成者 |
Kawaishi, Makoto
Yokote, Hideyuki
Kimura, Hideharu
Kasahara ,Kazuo
Nishio, Kazuto
|
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
NSCLC, mutant EGFR, HuCAL antibody |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
L858R point mutation in exon 21 of the EGFR gene, accounting for approximately 40% of non-small cell lung cancer (NSCLC)-associated EGFR mutations, has been known to hyper-respond to gefitinib, a selective EGFR tyrosine kinase inhibitor. From this view point, it is important to detect EGFR mutations. Immunohistochemistry (IHC) is commonly used to analyze the molecular status of several clinical specimens. We have developed specific antibodies recognizing the mutant EGFR (L858R) protein and characterized the antibodies by ELISA, Western blot, immunocytochemistry, and immunohistochemistry. Using any of these evaluation methods, we found an antibody, AbyD02889, which could detect the EGFR (L858R) protein with specificity. AbyD02889 may be a useful tool to detect the EGFR (L858R) mutation of NSCLC in the clinical situation. IHC using the mutant-specific anti-EGFR antibody will be a powerful assay to predict or select subpopulation sensitive to EGFR-TKI. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
The Kinki University Medical Association |
|
言語 |
en |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
03866092 |
| 開始ページ |
|
|
開始ページ |
67 |
| 終了ページ |
|
|
終了ページ |
74 |
| 書誌情報 |
en : ACTA MEDICA KINKI UNIVERSITY
巻 31,
号 2,
p. 67-74,
発行日 2006-12
|
AA0050842X-20061200-0067.pdf (1.2 MB)
